Skip to main content

Table 4 Prediction of stability at 6 months from administration of anti-fibrotic drugs in multivariate analysis

From: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis

variablemodel 1model 2model 3 (model 1 + model 2)
OR (95% CI)P-valueOR (95% CI)P-valueOR (95% CI)P-value
Change in SP-A in 3 months (%)0.88 (0.80–0.97)< 0.010.89 (0.76–0.98)< 0.05
Change in SP-D in 3 months (%)1.10 (0.98–1.05)0.281.04 (0.99–1.13)0.09
Change in KL-6 in 3 months (%)0.99 (0.95–1.03)0.670.99 (0.92–1.04)0.71
Change in SP-A in 6 months (%)0.90 (0.84–0.97)< 0.010.88 (0.76–0.96)< 0.01
Change in SP-D in 6 months (%)0.98 (0.92–1.03)0.370.98 (0.90–1.04)0.49
Change in KL-6 in 6 months (%)0.95 (0.90–1.01)0.050.96 (0.87–1.03)0.30
  1. OR odd’s ratio; SP surfactant protein; KL-6 Krebs von den Lungen-6